These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 25841722)

  • 1. Professor Shukui Qin: patient reported outcomes in study of axitinib or sorafenib in Asian patients with metastatic renal cell carcinoma.
    Qin S; Zhang S
    Chin Clin Oncol; 2015 Mar; 4(1):15. PubMed ID: 25841722
    [No Abstract]   [Full Text] [Related]  

  • 2. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
    Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI
    Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial.
    Escudier B; Michaelson MD; Motzer RJ; Hutson TE; Clark JI; Lim HY; Porfiri E; Zalewski P; Kannourakis G; Staehler M; Tarazi J; Rosbrook B; Cisar L; Hariharan S; Kim S; Rini BI
    Br J Cancer; 2014 Jun; 110(12):2821-8. PubMed ID: 24823696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial.
    Ueda T; Uemura H; Tomita Y; Tsukamoto T; Kanayama H; Shinohara N; Tarazi J; Chen C; Kim S; Ozono S; Naito S; Akaza H
    Jpn J Clin Oncol; 2013 Jun; 43(6):616-28. PubMed ID: 23630366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
    Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
    Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Case of Pancreatic Side Effects Resulting from Sorafenib and Axitinib Treatment of Stage IV Renal Cell Carcinoma.
    Kitamura Y; Yoshii H; Nishimoto K; Shinchi Y; Tokonabe S; Takao M; Daido Y
    Keio J Med; 2015; 64(4):62-4. PubMed ID: 26727578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial.
    Cella D; Escudier B; Rini B; Chen C; Bhattacharyya H; Tarazi J; Rosbrook B; Kim S; Motzer R
    Br J Cancer; 2013 Apr; 108(8):1571-8. PubMed ID: 23579211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aortic Dissection and Cardiac Dysfunction Emerged Coincidentally During the Long-Term Treatment with Angiogenesis Inhibitors for Metastatic Renal Cell Carcinoma.
    Takada M; Yasui T; Oka T; Shioyama W; Kuroda T; Nakai Y; Nishimura K; Mukai M; Fujita M
    Int Heart J; 2018 Sep; 59(5):1174-1179. PubMed ID: 30158382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Axitinib for the treatment of advanced renal cell carcinoma.
    Akaza H; Fukuyama T
    Expert Opin Pharmacother; 2014 Feb; 15(2):283-97. PubMed ID: 24328549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma.
    Escudier B; Rini BI; Motzer RJ; Tarazi J; Kim S; Huang X; Rosbrook B; English PA; Loomis AK; Williams JA
    Clin Genitourin Cancer; 2015 Aug; 13(4):328-337.e3. PubMed ID: 25816720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial.
    Hutson TE; Al-Shukri S; Stus VP; Lipatov ON; Shparyk Y; Bair AH; Rosbrook B; Andrews GI; Vogelzang NJ
    Clin Genitourin Cancer; 2017 Feb; 15(1):72-76. PubMed ID: 27498023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kidney cancer: Axitinib destined for second place?
    Payton S
    Nat Rev Urol; 2013 Dec; 10(12):678. PubMed ID: 24217676
    [No Abstract]   [Full Text] [Related]  

  • 13. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.
    Hutson TE; Escudier B; Esteban E; Bjarnason GA; Lim HY; Pittman KB; Senico P; Niethammer A; Lu DR; Hariharan S; Motzer RJ
    J Clin Oncol; 2014 Mar; 32(8):760-7. PubMed ID: 24297950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
    Miyake H; Imai S; Harada K; Fujisawa M
    Clin Genitourin Cancer; 2016 Feb; 14(1):e19-24. PubMed ID: 26382221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kidney cancer: AXIS trial data confirm axitinib as second-line option for mRCC.
    Payton S
    Nat Rev Urol; 2013 Jun; 10(6):308. PubMed ID: 23649292
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
    Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
    Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Axitinib as Second-line Treatment in Locally Advanced and Metastatic Renal Cell Carcinoma.
    Ueda K; Suekane S; Hirano T; Ogasawara N; Chikui K; Uemura K; Nakiri M; Nishihara K; Matsuo M; Igawa T
    Anticancer Res; 2018 Sep; 38(9):5387-5392. PubMed ID: 30194193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Axitinib in advanced renal-cell carcinoma.
    Yousaf N; Larkin J
    Lancet Oncol; 2013 Dec; 14(13):1245-6. PubMed ID: 24206641
    [No Abstract]   [Full Text] [Related]  

  • 19. Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.
    Pal SK; Jonasch E; Signorovitch JE; Reichmann WM; Li N; Liu Z; Perez JR; Vogelzang NJ
    J Med Econ; 2016; 19(5):462-8. PubMed ID: 26652893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New options for second-line therapy of advanced renal cancer.
    Bex A
    Lancet Oncol; 2013 May; 14(6):450-1. PubMed ID: 23598169
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.